Analysis of the effect of a novel therapeutic for type 2 diabetes on the proteome of a muscle cell line
Elevated serum retinol‐binding protein (RBP) concentration has been implicated in the development of insulin resistance and type 2 diabetes. Two series of small molecules have been designed to lower serum levels by reducing secretion of the transthyretin–RBP complex from the liver and enhancing RBP...
Gespeichert in:
| Veröffentlicht in: | Proteomics (Weinheim) 2016-01, Vol.16 (1), p.70-79 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 79 |
|---|---|
| container_issue | 1 |
| container_start_page | 70 |
| container_title | Proteomics (Weinheim) |
| container_volume | 16 |
| creator | Young, Pamela A. Leonard, Siobhán Martin, Darren S. D. Findlay, John B. C. |
| description | Elevated serum retinol‐binding protein (RBP) concentration has been implicated in the development of insulin resistance and type 2 diabetes. Two series of small molecules have been designed to lower serum levels by reducing secretion of the transthyretin–RBP complex from the liver and enhancing RBP clearance through the kidney. These small molecules were seen to improve glucose and insulin tolerance tests and to reduce body weight gain in mice rendered diabetic through a high fat diet. A proteomics study was conducted to better understand the effects of these compounds in muscle cells, muscle being the primary site for energy expenditure. One lead compound, RTC‐15, is seen to have a significant effect on proteins involved in fat and glucose metabolism. This could indicate that the compound is having a direct effect on muscle tissue to improve energy homeostasis as well as a whole body effect on circulating RBP levels. This newly characterized group of antidiabetic compounds may prove useful in the treatment and prevention of insulin resistance and obesity. |
| doi_str_mv | 10.1002/pmic.201500050 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1776659942</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1776659942</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4406-3e390b5ec5fc46859f2fb8cf1bdb35882510b9aed7c35d3d4df66c005853bed13</originalsourceid><addsrcrecordid>eNqNkUtv1TAQRi1ERUthyxJZYsMmF78TL8sVLZX6QCqIpeU4Y3DJq3YC3H-P05S7YENXfuic0cx8CL2iZEMJYe_GLrgNI1QSQiR5go6oorLQlaJP93fJD9HzlG4JoWWly2fokClZcsrEEfp20tt2l0LCg8fTd8DgPbhpeVncDz-hXX6jHWGegsN-iHjajYAZboKtYYIs9vfiGIcJhg5WtZuTawE7aFvchh5eoANv2wQvH85j9OX0w-ftx-Li-ux8e3JROCGIKjhwTWoJTnonVCW1Z76unKd1U3NZVUxSUmsLTem4bHgjGq-Uy6PnIWtoKD9Gb9e6uZ27GdJkupCWLmwPw5wMLUulpNaCPQKVguRFapHRN_-gt8Mc8-buqdwyFdVCbVbKxSGlCN6MMXQ27gwlZknLLGmZfVpZeP1Qdq47aPb433gyIFfgV2hh959y5tPl-ZYyqlX2itULaYLfe8_GH0aVvJTm69WZuTkV9L26vDFb_gfnlK4I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1753901484</pqid></control><display><type>article</type><title>Analysis of the effect of a novel therapeutic for type 2 diabetes on the proteome of a muscle cell line</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Young, Pamela A. ; Leonard, Siobhán ; Martin, Darren S. D. ; Findlay, John B. C.</creator><creatorcontrib>Young, Pamela A. ; Leonard, Siobhán ; Martin, Darren S. D. ; Findlay, John B. C.</creatorcontrib><description>Elevated serum retinol‐binding protein (RBP) concentration has been implicated in the development of insulin resistance and type 2 diabetes. Two series of small molecules have been designed to lower serum levels by reducing secretion of the transthyretin–RBP complex from the liver and enhancing RBP clearance through the kidney. These small molecules were seen to improve glucose and insulin tolerance tests and to reduce body weight gain in mice rendered diabetic through a high fat diet. A proteomics study was conducted to better understand the effects of these compounds in muscle cells, muscle being the primary site for energy expenditure. One lead compound, RTC‐15, is seen to have a significant effect on proteins involved in fat and glucose metabolism. This could indicate that the compound is having a direct effect on muscle tissue to improve energy homeostasis as well as a whole body effect on circulating RBP levels. This newly characterized group of antidiabetic compounds may prove useful in the treatment and prevention of insulin resistance and obesity.</description><identifier>ISSN: 1615-9853</identifier><identifier>EISSN: 1615-9861</identifier><identifier>DOI: 10.1002/pmic.201500050</identifier><identifier>PMID: 26573124</identifier><language>eng</language><publisher>Germany: Blackwell Publishing Ltd</publisher><subject>Animals ; C2C12 ; Cell biology ; Cell Line ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - metabolism ; Glucose - metabolism ; Hypoglycemic Agents - chemistry ; Hypoglycemic Agents - pharmacology ; Insulin Resistance ; Mice ; Muscle Cells - drug effects ; Muscle Cells - metabolism ; Protein Interaction Maps - drug effects ; Proteome - metabolism ; Retinol-binding protein ; Retinol-Binding Proteins, Plasma - metabolism ; RTC-15 ; Type 2 diabetes</subject><ispartof>Proteomics (Weinheim), 2016-01, Vol.16 (1), p.70-79</ispartof><rights>2015 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim</rights><rights>2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.</rights><rights>2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4406-3e390b5ec5fc46859f2fb8cf1bdb35882510b9aed7c35d3d4df66c005853bed13</citedby><cites>FETCH-LOGICAL-c4406-3e390b5ec5fc46859f2fb8cf1bdb35882510b9aed7c35d3d4df66c005853bed13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpmic.201500050$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpmic.201500050$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26573124$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Young, Pamela A.</creatorcontrib><creatorcontrib>Leonard, Siobhán</creatorcontrib><creatorcontrib>Martin, Darren S. D.</creatorcontrib><creatorcontrib>Findlay, John B. C.</creatorcontrib><title>Analysis of the effect of a novel therapeutic for type 2 diabetes on the proteome of a muscle cell line</title><title>Proteomics (Weinheim)</title><addtitle>Proteomics</addtitle><description>Elevated serum retinol‐binding protein (RBP) concentration has been implicated in the development of insulin resistance and type 2 diabetes. Two series of small molecules have been designed to lower serum levels by reducing secretion of the transthyretin–RBP complex from the liver and enhancing RBP clearance through the kidney. These small molecules were seen to improve glucose and insulin tolerance tests and to reduce body weight gain in mice rendered diabetic through a high fat diet. A proteomics study was conducted to better understand the effects of these compounds in muscle cells, muscle being the primary site for energy expenditure. One lead compound, RTC‐15, is seen to have a significant effect on proteins involved in fat and glucose metabolism. This could indicate that the compound is having a direct effect on muscle tissue to improve energy homeostasis as well as a whole body effect on circulating RBP levels. This newly characterized group of antidiabetic compounds may prove useful in the treatment and prevention of insulin resistance and obesity.</description><subject>Animals</subject><subject>C2C12</subject><subject>Cell biology</subject><subject>Cell Line</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Glucose - metabolism</subject><subject>Hypoglycemic Agents - chemistry</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Insulin Resistance</subject><subject>Mice</subject><subject>Muscle Cells - drug effects</subject><subject>Muscle Cells - metabolism</subject><subject>Protein Interaction Maps - drug effects</subject><subject>Proteome - metabolism</subject><subject>Retinol-binding protein</subject><subject>Retinol-Binding Proteins, Plasma - metabolism</subject><subject>RTC-15</subject><subject>Type 2 diabetes</subject><issn>1615-9853</issn><issn>1615-9861</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtv1TAQRi1ERUthyxJZYsMmF78TL8sVLZX6QCqIpeU4Y3DJq3YC3H-P05S7YENXfuic0cx8CL2iZEMJYe_GLrgNI1QSQiR5go6oorLQlaJP93fJD9HzlG4JoWWly2fokClZcsrEEfp20tt2l0LCg8fTd8DgPbhpeVncDz-hXX6jHWGegsN-iHjajYAZboKtYYIs9vfiGIcJhg5WtZuTawE7aFvchh5eoANv2wQvH85j9OX0w-ftx-Li-ux8e3JROCGIKjhwTWoJTnonVCW1Z76unKd1U3NZVUxSUmsLTem4bHgjGq-Uy6PnIWtoKD9Gb9e6uZ27GdJkupCWLmwPw5wMLUulpNaCPQKVguRFapHRN_-gt8Mc8-buqdwyFdVCbVbKxSGlCN6MMXQ27gwlZknLLGmZfVpZeP1Qdq47aPb433gyIFfgV2hh959y5tPl-ZYyqlX2itULaYLfe8_GH0aVvJTm69WZuTkV9L26vDFb_gfnlK4I</recordid><startdate>201601</startdate><enddate>201601</enddate><creator>Young, Pamela A.</creator><creator>Leonard, Siobhán</creator><creator>Martin, Darren S. D.</creator><creator>Findlay, John B. C.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7QP</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>201601</creationdate><title>Analysis of the effect of a novel therapeutic for type 2 diabetes on the proteome of a muscle cell line</title><author>Young, Pamela A. ; Leonard, Siobhán ; Martin, Darren S. D. ; Findlay, John B. C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4406-3e390b5ec5fc46859f2fb8cf1bdb35882510b9aed7c35d3d4df66c005853bed13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>C2C12</topic><topic>Cell biology</topic><topic>Cell Line</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Glucose - metabolism</topic><topic>Hypoglycemic Agents - chemistry</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Insulin Resistance</topic><topic>Mice</topic><topic>Muscle Cells - drug effects</topic><topic>Muscle Cells - metabolism</topic><topic>Protein Interaction Maps - drug effects</topic><topic>Proteome - metabolism</topic><topic>Retinol-binding protein</topic><topic>Retinol-Binding Proteins, Plasma - metabolism</topic><topic>RTC-15</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Young, Pamela A.</creatorcontrib><creatorcontrib>Leonard, Siobhán</creatorcontrib><creatorcontrib>Martin, Darren S. D.</creatorcontrib><creatorcontrib>Findlay, John B. C.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Proteomics (Weinheim)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Young, Pamela A.</au><au>Leonard, Siobhán</au><au>Martin, Darren S. D.</au><au>Findlay, John B. C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analysis of the effect of a novel therapeutic for type 2 diabetes on the proteome of a muscle cell line</atitle><jtitle>Proteomics (Weinheim)</jtitle><addtitle>Proteomics</addtitle><date>2016-01</date><risdate>2016</risdate><volume>16</volume><issue>1</issue><spage>70</spage><epage>79</epage><pages>70-79</pages><issn>1615-9853</issn><eissn>1615-9861</eissn><abstract>Elevated serum retinol‐binding protein (RBP) concentration has been implicated in the development of insulin resistance and type 2 diabetes. Two series of small molecules have been designed to lower serum levels by reducing secretion of the transthyretin–RBP complex from the liver and enhancing RBP clearance through the kidney. These small molecules were seen to improve glucose and insulin tolerance tests and to reduce body weight gain in mice rendered diabetic through a high fat diet. A proteomics study was conducted to better understand the effects of these compounds in muscle cells, muscle being the primary site for energy expenditure. One lead compound, RTC‐15, is seen to have a significant effect on proteins involved in fat and glucose metabolism. This could indicate that the compound is having a direct effect on muscle tissue to improve energy homeostasis as well as a whole body effect on circulating RBP levels. This newly characterized group of antidiabetic compounds may prove useful in the treatment and prevention of insulin resistance and obesity.</abstract><cop>Germany</cop><pub>Blackwell Publishing Ltd</pub><pmid>26573124</pmid><doi>10.1002/pmic.201500050</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1615-9853 |
| ispartof | Proteomics (Weinheim), 2016-01, Vol.16 (1), p.70-79 |
| issn | 1615-9853 1615-9861 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1776659942 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Animals C2C12 Cell biology Cell Line Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Glucose - metabolism Hypoglycemic Agents - chemistry Hypoglycemic Agents - pharmacology Insulin Resistance Mice Muscle Cells - drug effects Muscle Cells - metabolism Protein Interaction Maps - drug effects Proteome - metabolism Retinol-binding protein Retinol-Binding Proteins, Plasma - metabolism RTC-15 Type 2 diabetes |
| title | Analysis of the effect of a novel therapeutic for type 2 diabetes on the proteome of a muscle cell line |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T17%3A39%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analysis%20of%20the%20effect%20of%20a%20novel%20therapeutic%20for%20type%202%20diabetes%20on%20the%20proteome%20of%20a%20muscle%20cell%20line&rft.jtitle=Proteomics%20(Weinheim)&rft.au=Young,%20Pamela%20A.&rft.date=2016-01&rft.volume=16&rft.issue=1&rft.spage=70&rft.epage=79&rft.pages=70-79&rft.issn=1615-9853&rft.eissn=1615-9861&rft_id=info:doi/10.1002/pmic.201500050&rft_dat=%3Cproquest_cross%3E1776659942%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1753901484&rft_id=info:pmid/26573124&rfr_iscdi=true |